CLINICAL_TRIALS
trial_result
· 2013-10-31
Clinical Trial Update: Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome [Phase 2]
Summary
Phase 2 trial evaluating once-daily pramipexole (BI-Sifrol) for 6 weeks in patients with Restless Legs Syndrome; the study status is completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Restless Legs Syndrome | Phase 2 | Status: COMPLETED